Condition (MeSH)
HIV Seropositivity
ClinicalTrials.gov lists 194 trials for HIV Seropositivity or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 16.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
194 of the 194 trials are tagged with HIV Seropositivity itself; the rest are tagged with a narrower condition beneath it.
When did HIV Seropositivity trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 7 |
| 2024 | 2 |
| 2023 | 9 |
| 2022 | 7 |
| 2021 | 12 |
| 2020 | 15 |
| 2019 | 7 |
| 2018 | 7 |
| 2017 | 8 |
| 2016 | 5 |
Showing 10 of 28 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 1 trials starting in 2026 and about 4 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 138 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are HIV Seropositivity trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 11 |
| Phase 1/2 | 4 |
| Phase 2 | 20 |
| Phase 2/3 | 1 |
| Phase 3 | 12 |
| Phase 4 | 14 |
| Not applicable | 56 |
| Observational | 76 |
How many HIV Seropositivity trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 5 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 5 |
| Completed | 146 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most HIV Seropositivity trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 16 |
| ANRS, Emerging Infectious Diseases | 5 |
| Centers for Disease Control and Prevention | 3 |
| Fondation Ophtalmologique Adolphe de Rothschild | 3 |
| National Cancer Institute (NCI) | 3 |
Showing 5 of 6 sponsors.
Which drugs are being tested for HIV Seropositivity? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Raltegravir | 4 |
| LAMIVUDINE | 3 |
| Rintatolimod | 3 |
| Zidovudine | 2 |
| Thymopentin | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| gp160 Vaccine (Immuno-AG) | 2 |
| Sulphadoxine-Pyrimethamine | 2 |
| tenofovir disproxil fumarate | 2 |
| AG chemotherapy | 1 |
| BrECADD | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do HIV Seropositivity trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| MALARIA | 93 | 1 |
| Hospitalization | 48 | 2 |
| NEUTROPHIL COUNT DECREASED | 41 | 1 |
| Febrile neutropenia | 38 | 1 |
| Sent to compulsory drug rehabilitation programs | 27 | 1 |
Showing 5 of 10 adverse events.
Which publications cover HIV Seropositivity? (809)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Predictors of HIV seroconversion in Botswana. | AIDS (London, England) | 2025 | Yes |
| Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. | The lancet. HIV | 2024 | Yes |
| Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies. | AIDS research and therapy | 2024 | Yes |
| A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV. | AIDS (London, England) | 2024 | Yes |
| HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. | The lancet. HIV | 2024 | Yes |
Showing 5 of 809 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.